These tumors, in comparison to other types of NHL, have high expression of PD1, PD-L1, and/or PD-L2, which forms the basis for CPI in these conditions, and therapeutic responses have been seen in these diseases in early phase clinical trials. This evidence concerns the gene CD274 and non-Hodgkin lymphoma.